antidepressants

ApprovedSmall molecule

Johnson & Johnson

antidepressants is one of 55 small molecule programs targeting Bulimia Nervosa. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bulimia NervosaActive, not recruiting

Back PainActive, not recruiting

Bulimia NervosaApproved

Active, not recruiting

Back PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

87 competitors in Back Pain

#DrugCompanyPhaseTrials

Aleve

Alnylam Pharmaceuticals

Approved

5 2

Lodosyn

LLaTonya J. Hickson

Approved

—3

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 4

Aspercreme Warming

AAveritas Pharma, Inc.

Phase 3

1 5

Suboxone

IIndivior Inc.

Phase 3

1 6

Botox

AbbVie

Phase 3

1 7

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 8

Buprenorphine IV

PPurdue Pharma LP

Phase 3

1 9

Standard Medical Care

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

1 10

antidepressants

Johnson & Johnson

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Depression2 trials

A Study of Chinese Medicine Treating Depression

Unknown status·TThe Third Affiliated Hospital of Beijing University of Chinese Medicine··NCT02873234·4,600 enrolled

Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression

Completed·—·Phase 3·NCT02624102·76 enrolled

Transcranial Magnetic Stimulation1 trial

The Study About Mechanism of Transcranial Magnetic Stimulation Treatment of Depression Using Medical Imaging

Unknown status·XXi'an Jiaotong University·Phase 1·NCT03500029·240 enrolled

Mindfulness1 trial

Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy

Completed·CCentre for Addiction and Mental Health·Phase 4·NCT00183560·184 enrolled

Musculoskeletal Pain1 trial

Stepped Care for Depression and Musculoskeletal Pain

Completed·IIndiana University·Phase 4·NCT00118430·500 enrolled

Treatment1 trial

ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT00264069·2,622 enrolled

3 more indications

Back pain1 trial

Combined Interventions for Treating Depression and Chronic Back Pain

Completed·KKaiser Permanente·N/A·NCT00158275·71 enrolled

Bulimia Nervosa1 trial

Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.

Completed·—·Phase 4·NCT02359513·51 enrolled

Major Depression1 trial

Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care.

Unknown status·FFundació Sant Joan de Déu··NCT02245373·263 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for antidepressants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — antidepressants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for antidepressants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Johnson & Johnson

antidepressants

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Depression2 trials

Transcranial Magnetic Stimulation1 trial

Mindfulness1 trial

Musculoskeletal Pain1 trial

Treatment1 trial

Back pain1 trial

Bulimia Nervosa1 trial

Major Depression1 trial

References

Drug Info

Quick Facts

Related News